Business
DXS International plc (AQSE: DXSP): Half-year...
DXS International plc reported a decrease in revenue to £1,684,712 for the half-year ending 31 October 2025, down 2.6% from £1,730,829 in the prior year period, and incurred a loss after tax of (£99,041) compared to a profit of £1,131, primarily due to a reduction in Grant Income. Despite this, available cash increased to £160,400, and the company highlighted positive feedback on its new SMART Referral solution, progress on its Secondary Care pilot, and the imminent market readiness of its Cholesterol prototype, which targets significant NHS incentives. The company anticipates revenue growth around April 2026 and remains confident in meeting full-year market expectations for April FY 2026. Disclaimer*
About this update from Dxs International Plc
[{"type":"text","content":"\n\n \n \n\n DXS International plc (AQSE: DXSP): Half-year Financial Report\n\nDXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc (\"DXS\" or the \"Company\"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2025. H1 2025 Financial highlights: Core recurring revenue model remains resilient. Revenue decreased by 2.6% to £1,684,712 (H1 2024 - £1,730,829) in the six months to 31 October 2025 (\"Period\"). Administration costs decreased by 5% in the Period (H1 2024 -£87,474)Loss after tax in the Period of (£99,041) compared to a profit of £1,131 in H1 2024, a change of (£100,172). This was largely due to Grant Income reducing by £164,409. It should also be noted that all development costs for ongoing R&D are now included in the P&L, which is in line with new HMRC guidelines.Available cash at the Period end was £160,400 (H1 2024 - £96,431), plus unutilised debtor drawdowns of £19,512 (H1 2024 £256,670). Operational highlights: The deployment of our new SMART Referral solution, Next-Gen, continues to provide exceptionally positive feedback from early adopter users. This is important as this is the potential trigger for Integrated Care Boards (ICBs) to move non-DXS practices to Next-Gen, an initiative we have been working on for some time that should potentially increase our Annual Recurring Revenue (ARR).Our Secondary Care pilot, intended to remove the need for manual referral input by hospital staff into hospital systems, is running well. This should provide a new future revenue stream in due course.Tackling Cardiovascular Disease (CVD) remains a top NHS priority and therefore, armed with the recent positive York Health Economic Consortium evaluation outcome, the Cholesterol prototype is expected to be market ready imminently. We will be well positioned to provide GP Primary Care Networks (PCN) (1 PCN =on average 5 GP practices) with a medicine optimisation solution that can help them achieve the new 2026 CVD targets, which if met, are worth approximately £49,000 NHS incentive per practice – up from £17,000 per practice last year.Completed a hypertension project for a PCN in the East of England with excellent outcomes.We have continued our committed investment in R&D, even though this is not ref...